PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: Inter-pathologist variability is higher than assay variability

163Citations
Citations of this article
136Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Assessment of programmed cell death ligand 1 (PD-L1) immunohistochemical staining is used for decision on treatment with programmed cell death 1 and PD-L1 checkpoint inhibitors in lung adenocarcinomas and squamous cell carcinomas. This study aimed to compare the staining properties of tumor cells between the antibody clones 28-8, 22C3, SP142, and SP263 and investigate interrater variation between pathologists to see if these stainings can be safely evaluated in the clinical setting. Using consecutive sections from a tissue microarray with tumor tissue from 55 resected lung cancer cases, staining with five PD-L1 assays (28-8 from two different vendors, 22C3, SP142, and SP263) was performed. Seven pathologists individually evaluated the percentage of positive tumor cells, scoring each sample applying cutoff levels used in clinical studies: <1% positive tumor cells (score 0), 1-4% (score 1), 5-9% (score 2), 10-24% (score 3), 25-49% (score 4), and >50% positive tumor cells (score 5). Pairwise analysis of antibody clones showed weighted kappa values in the range of 0.45-0.91 with the highest values for comparisons with 22C3 and 28-8 and the lowest involving SP142. Excluding SP142 resulted in kappa 0.75-0.91. Weighted kappa for interobserver variation between pathologists was 0.71-0.96. Up to 20% of the cases were differently classified as positive or negative by any pathologist compared with consensus score using ≥1% positive tumor cells as cutoff. A significantly better agreement between pathologists was seen using ≥50% as cutoff (0-5% of cases). In conclusion, the concordance between the PD-L1 antibodies 22C3, 28-8 and SP263 is relatively good when evaluating lung cancers and suggests that any one of these assays may be sufficient as basis for decision on treatment with nivolumab, pembrolizumab, and durvalumab. The scoring of the pathologist presents an intrinsic source of error that should be considered especially at low PD-L1 scores.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Brunnström, H., Johansson, A., Westbom-Fremer, S., Backman, M., Djureinovic, D., Patthey, A., … Micke, P. (2017). PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: Inter-pathologist variability is higher than assay variability. Modern Pathology, 30(10), 1411–1421. https://doi.org/10.1038/modpathol.2017.59

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 36

55%

Researcher 16

25%

Professor / Associate Prof. 7

11%

Lecturer / Post doc 6

9%

Readers' Discipline

Tooltip

Medicine and Dentistry 46

73%

Biochemistry, Genetics and Molecular Bi... 8

13%

Agricultural and Biological Sciences 5

8%

Pharmacology, Toxicology and Pharmaceut... 4

6%

Article Metrics

Tooltip
Mentions
News Mentions: 3

Save time finding and organizing research with Mendeley

Sign up for free